12. Resource Management

The company discloses what qualitative and quantitative goals it has set itself with regard to its resource efficiency, in particular its use of renewables, the increase in raw material productivity and the reduction in the usage of ecosystem services, which measures and strategies it is pursuing to this end, how these are or will be achieved, and where it sees there to be risks.

While many of our industrial products like enzymes or our incubator projects have a clear positive sustainability impact for our customers we still strive to minimize the ecological footprint of our own operation. Here the most material areas from our operations to focus on are:
Here we aspire to reduce the primary resource consumption of our production, reduce our CO2 footprint and avoid unnecessary waste to landfill. For our inaugural ESG & sustainability report we have focused on Scope 1 and Scope 2 emissions. We aspire to incorporate Scope 3 emissions at a later stage in time.

We have issued our inaugural ESG and Sustainability Report in 2022. Hence, no previous environmental targets were communicated and can be measured for achievement.

Future targets: 

Targets to minimize the environmental impact from our operations:

By 2032, reduce Scope 1-2 GHG emissions by 30% in relation to current revenue base
By 2050, Scope 1-2 GHG emissions to net zero

Detailed Actions
•Switch to sustainable sourcing of primary energy
•Building renovation and change of cooling/heating design
•Electrification of processes and transport
•Establish employee best idea contest on cost, energy savings and process optimization

The BRAIN Group uses a limited amount of primary resources for its own production and service generation. Most of our products directy contribute to a biological production and, hence, lower primary resource consumptions at our customers. While we aim to furher reduce our own ecological footprint by lowering GHG emissions we view ourselves having a net positive contribution. It is our aim for future ESG reporting to incorporate a Scope 3 analysis.

This is our first reporting period and we have not defined any clear targets beforehand. Hence we are unfortunately unable to provide any information on targets achieved/not achieved in the past.

As a B2B supplier most of the work within the group does not relate to the production of a final product. We develop biotechnology-based solutions to solve our customers' problems. So while we can control who we work with and what materials we use in development, the use case of the final product is in the control of our customer.

So far we have not conducted a Scope 3 analysis.